Article
Waltham, MA-Interleukin Genetics Inc. has received a U.S. patent for a method that uses specific genetic markers to identify people with diabetes who are at an increased risk of retinopathy.
Alcon agrees to purchase LENSAR
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
ZEISS VISULAS Combi availability expands to Canada
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Nicox announces last patient completed final visit in Whistler Phase 3b clinical trial
Importance of evaluating cerebrospinal fluid at vitreoretinal lymphoma diagnosis